echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > The long-term effect of "first-in-class" psoriasis external therapy is obvious...

    The long-term effect of "first-in-class" psoriasis external therapy is obvious...

    • Last Update: 2021-03-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Today, Dermavant Sciences announced that the company's tapinarof emulsion (1%) has obtained positive results in an interim analysis of long-term open labeling studies for adult patients with plaque-like psoriasis.
    -term analysis showed that long-term use of tapinarof could further improve the patient's skin symptoms, and that even if the patient stopped taking the drug after the skin symptoms had disappeared, the therapeutic effect could continue for nearly four months.
    Tapinarof is a "first-in-class" aromatic hydrocarbon regulator (TAMA).
    it's worth noting that the innovative treatment, first approved in China in 2019, is called benvitimod cream and was first added to the 2020 list of medicare drugs in December.
    psoriasis, also known as psoriasis, is a common chronic, autoimmune inflammatory skin disease.
    there are 125 million psoriasis patients worldwide and about 8 million in China.
    for patients with more severe symptoms, psoriasis has a significant impact on their quality of life.
    At present, psoriasis preferred external treatment options are mostly glucosticoids and vitamin D derivatives, glucosal hormones although the effect is fast, but after the suspension of the drug the disease is easy to repeat, and long-term use has a safety risk.
    Tapinarof is a "first-in-class" aromatic hydrocarbon regulator.
    is a natural compound isolated from the symbic bacterial metabolites of soil worms.
    was originally developed by Welichem Biotech.
    , the drug's research and development interests outside Greater China have been reshounded several times, and were won by Dermavant in 2018.
    Tapinarof as a non-hormonal small molecule drug with a molecular weight of only 254 Da, with good skin permeability.
    aromatic hydrocarbons have an important role to play in regulating autoimmune response.
    Tapinarof inhibits the inflammatory response mediated by IL-17 by regulating the function of aromatic receptors.
    IL-17 signaling path is arguably the "star path" for psoriasis, and psoriasis treatments targeting IL-17 include Cosentyx, developed by Novartis, Bimekizumab, developed by UCB, and Taltz, developed by Lilly.
    in a long-term study called PSOARING 3, patients who had participated in key Phase 3 clinical trials PSOARING 1 and PSOARING 2 continued to receive 40 weeks of tapinarof therapy.
    results showed that 57.3% of subjects with skin symptoms met the standard of 0 (PGA) on behalf of skin symptoms completely cleared, or 1 (almost complete removal of skin symptoms) after treatment.
    previously, the proportion of patients who met this standard in PSOARING 1 and PSOARING 2 clinical trials with a 12-week course of treatment was 35.4% and 40.2%.
    means that as tapinarof lasts longer, it shows better results.
    , the study also assessed the results of a patient who had their skin symptoms completely cleared after they stopped taking the drug.
    -term analysis showed that patients with a PGA score of 0 at the time of joining the PSOARING 3 study had a mid-range time of approximately 115 days for skin symptoms to worsen (defined as PGA-gt;2) after discontinuation of medication.
    "Tapinarof's effect after the drug was stopped is unique to this new molecular entity. Dr. Robert Bissonnette, chief executive of Innovaderm Research, a dermatologist at
    who has been involved in five tapinarof clinical studies, said, "This interim analysis shows that tapinarof, if approved, can help patients who have long been plagued by psoriasis control symptoms."
    said it expects to complete the PSOARING 3 study in the first quarter of this year and plans to submit a new drug application to the FDA by the middle of this year.
    addition, this innovative therapy for the treatment of adesthetic dermatitis has been developed in the clinical phase 2.
    May 2019, China's State Drug Administration announced that it had approved the listing of Benvimod cream for local treatment of mild to moderately stable psoriasis in adults through a priority review approval process.
    this is the first time this innovative therapy has been approved worldwide.
    addition to being included in Health Insurance for the first time by the end of 2020, it has also been included in the first edition of the China Children's Psoriasis Guidelines, which will be completed in 2020.
    : This article is intended to introduce medical and health research, not treatment options recommended.
    if you need guidance on treatment options, visit a regular hospital.
    : s1. Positive Data from PSARING 3 Support Long-Term Use of Tapinarof Cream in Adults with Plaque Psoriasis, with On-Therapy and Remitt Benefits. Retrived February 18, 2021, from the psoriasis "new star" Ben Wimmod first entered the health care catalog, external treatment will welcome the new changes Retrieved February 18, 2021, from the Chinese medicine industry. Retrieved February 18, 2021, from ten years grinding a sword! Zhongyu Pharmaceuticals obtained the Benvimod Cream National Class 1 New Drug Certificate. Retrieved February 18, 2021, from
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.